understanding nsclc treatments for less common mutations: alk, braf, ros1, her2, met
Published 2 months ago • 569 plays • Length 5:41Download video MP4
Download video MP3
Similar videos
-
18:41
extreme rare mutations in lung cancer (ros1, trk, her2): treatment opportunities
-
5:53
targeted therapy in non-small cell lung cancer
-
3:30
immunotherapy treatments for non-small cell lung cancer (nsclc)
-
6:14
understanding biomarker testing in non-small cell lung cancer
-
6:30
treatment options for alk/ros1 mutation
-
47:57
lung cancer new treatment 2023
-
1:06
dr. goldman on targeted therapy options for egfr-, alk-, and ros1-mutated nsclc
-
1:49
what targeted therapies are used for people with the ros1 mutation?
-
21:08
pathologic testing for alk and ros1 aberrations in nsclc | frédérique penault-llorca
-
5:03
understanding nsclc treatment when you have an egfr mutation
-
14:45
potential and progress in targeting less common markers: her2, braf, kras, met, trk, and ret
-
21:10
targeting her2, braf, kras, met
-
57:49
understanding her2 alterations in advanced non-squamous nsclc
-
6:44
treatment options for lung cancer mutations & contingencies
-
0:42
understanding the ros1 mutation with lysa buonanno and dr. david carbone #ros1 #nsclc #lungcancer
-
0:41
treatment options for metastatic non-small cell lung cancer with no actionable mutations in 1l
-
2:47
how do doctors treat lung cancer with ros1 mutations?
-
9:33
second-line brigatinib for alk/ros1-rearranged nsclc